Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Haematologica|November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
American Journal of Hematology|February 24, 2018
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centersSylvain P Chantepie, Sylvain Garciaz, Emmanuelle Tchernonog, et al.
Haematologica|May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND studyGabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
American Journal of Hematology|December 2, 2017
"Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gainElise Chapiro, Claude Lesty, Clémentine Gabillaud, et al.
Blood Advances|October 20, 2023
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Pierre-Julien Viailly, Fanny Drieux, et al.
Blood|June 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatmentAlexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Blood Advances|August 30, 2021
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Cédric Rossi, Pierre Sesques, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
Pageof 6